Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications

about

Clinical-Pathological Conference Series from the Medical University of Graz : Case No 154: 32-year-old computer software engineer with nodular mass in the liver.The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.

P2860

Q36885671-376BC03B-A5B0-4D52-8118-7E9D01160D9B Q38695102-34D0BA48-96F9-4C4B-B62A-66701398AC6D

P2860

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications

Item

http://www.wikidata.org/entity/Q37772579

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Somatostatin receptor biology ...... part 2--clinical implications

@en

Somatostatin receptor biology ...... part 2--clinical implications.

@nl

type

Item

label

Somatostatin receptor biology ...... part 2--clinical implications

@en

Somatostatin receptor biology ...... part 2--clinical implications.

@nl

prefLabel

Somatostatin receptor biology ...... part 2--clinical implications

@en

Somatostatin receptor biology ...... part 2--clinical implications.

@nl

P1476

Somatostatin receptor biology ...... part 2--clinical implications

@en

P2093

Ashley Grossman

http://www.w3.org/2001/XMLSchema#string

Dorota Dworakowska

http://www.w3.org/2001/XMLSchema#string

Mehtap Cakir

http://www.w3.org/2001/XMLSchema#string

P2860

Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis

[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.

Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.

Ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery

Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells.

Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.

Somatostatin receptor subtype gene expression in pituitary adenomas.

Medical management of thyrotropin-secreting pituitary adenomas.

Opportunities in somatostatin research: biological, chemical and therapeutic aspects.

P304

2585-2591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1111/J.1582-4934.2010.01125_1.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45187224

http://www.w3.org/2001/XMLSchema#string

P698

20629988

http://www.w3.org/2001/XMLSchema#string

P921

neuroendocrine tumor

cell surface receptor

membrane proteins

pituitary neoplasm

pituitary adenoma

P932

4373478

http://www.w3.org/2001/XMLSchema#string

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications

about

P2860

P2860

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932